RSV vaccine uptake will start slower than shingles shot: GSK CEO

UK house prices rise in January, Novo Nordisk obesity drug sales surge – as it happened, Business

SEC Filing

GSK invests €250M-plus in vaccine manufacturing as Shingrix surges, RSV launch kicks off

CNBC Transcript: GSK CEO Emma Walmsley Speaks with CNBC's Jim Cramer Live During CNBC's Healthy Returns Summit Today - CNBC Events

Shingrix Archives - PharmaLive

RSV Shot Is Approved for Infants - The New York Times

A Surprising Finding Leads to an RSV Vaccine Breakthrough - Bloomberg

GSK Bets on Further Growth After Shingles and RSV Vaccines Boost Sales - WSJ

New RSV Vaccines Aren't Covered by Some Health Insurance Plans - The New York Times

How a big pharma company stalled a potentially lifesaving vaccine in pursuit of bigger profits

RSV vaccine race heats up with highly effective GSK shot